The Rheumatoid Arthritis Quality of Life Questionnaire
Purpose
determine quality of life with Rheumatoid Arthritis
The Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) is a disease-specific
patient-reported outcome measure which determines the effect
rheumatoid arthritis has on a patient's
quality of life.[1] The RAQoL has 30 items with a yes and no response format[2] and takes about six minutes to complete.[3]
Scores on the RAQoL are a sum of all the individual item scores with a range from 0-30, with a lower score indicating better quality of life.[4] The RAQoL is a self-assessment
questionnaire, meaning patients fill out the survey themselves in order to avoid experimental error.[5]
History
The RAQoL was developed by Galen Research, the
University of Leeds and the
Academic Hospital Maastricht, and was first published in 1997.[6] It was the first patient completed quality of life questionnaire that focused on rheumatoid arthritis [7] and is distinct from other questionnaires as it includes physical contact as a dimension of quality of life.[8] Other dimensions include activities of daily living, social interaction/function, emotions, mood and recreation and pastimes.[9]
International Use
Since its development, the RAQOL has been translated into 33 languages other than Dutch and UK English.[10] Validation studies have been performed in countries such as Sweden,[11] Argentina[12] and Australia[13] in order to confirm the responsiveness and validity of the language adaptations.
The RAQoL has been used in
clinical studies in order to confirm the efficacy of proposed treatments of rheumatoid arthritis. It has been utilized in order to confirm the efficacy of
tocilizumab[14][15] and
infliximab.[16][17]
^Maska, L.; Anderson, J.; Michaud, K. (November 2011). "Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL)". Arthritis Care & Research. 63 (Supplement S11): S4–S13.
doi:
10.1002/acr.20620.
PMID22588760.
^Marra, Carlo A.; Woolcott, John C.; Kopec, Jacek A.; Shojania, Kamran; Offer, Robert; Brazier, John E.; Esdaile, John M.; Anis, Aslam H. (April 2005). "A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis". Social Science & Medicine. 60 (7): 1571–1582.
doi:
10.1016/j.socscimed.2004.08.034.
PMID15652688.
^Lillegraven, Siri; Kvien, Tore K. (October 2007). "Measuring disability and quality of life in established rheumatoid arthritis". Best Practice & Research Clinical Rheumatology. 21 (5): 827–840.
doi:
10.1016/j.berh.2007.05.004.
PMID17870030.
^"Measures Database". Galen-Research.com. Galen Research. Retrieved 2 October 2013.
^Eberhardt, Kerstin; Duckberg, Siv; Larsson, Britt-Marie; Johnson, Pia Malcus; Nived, Kerstin (July 2009). "Measuring health related quality of life in patients with rheumatoid arthritis – reliability, validity, and responsiveness of a Swedish version of RAQoL". Scandinavian Journal of Rheumatology. 31 (1): 6–12.
doi:
10.1080/030097402317255291.
PMID11922201.
S2CID42285569.
^Quinn, Mark A.; Conaghan, Philip G.; O'Connor, Philip J.; Karim, Zunaid; Greenstein, Adam; Brown, Andrew; Brown, Clare; Fraser, Alexander; Jarret, Stephen; Emery, Paul (January 2005). "Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial". Arthritis & Rheumatism. 52 (1): 27–35.
doi:
10.1002/art.20712.
PMID15641102.
The Rheumatoid Arthritis Quality of Life Questionnaire
Purpose
determine quality of life with Rheumatoid Arthritis
The Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) is a disease-specific
patient-reported outcome measure which determines the effect
rheumatoid arthritis has on a patient's
quality of life.[1] The RAQoL has 30 items with a yes and no response format[2] and takes about six minutes to complete.[3]
Scores on the RAQoL are a sum of all the individual item scores with a range from 0-30, with a lower score indicating better quality of life.[4] The RAQoL is a self-assessment
questionnaire, meaning patients fill out the survey themselves in order to avoid experimental error.[5]
History
The RAQoL was developed by Galen Research, the
University of Leeds and the
Academic Hospital Maastricht, and was first published in 1997.[6] It was the first patient completed quality of life questionnaire that focused on rheumatoid arthritis [7] and is distinct from other questionnaires as it includes physical contact as a dimension of quality of life.[8] Other dimensions include activities of daily living, social interaction/function, emotions, mood and recreation and pastimes.[9]
International Use
Since its development, the RAQOL has been translated into 33 languages other than Dutch and UK English.[10] Validation studies have been performed in countries such as Sweden,[11] Argentina[12] and Australia[13] in order to confirm the responsiveness and validity of the language adaptations.
The RAQoL has been used in
clinical studies in order to confirm the efficacy of proposed treatments of rheumatoid arthritis. It has been utilized in order to confirm the efficacy of
tocilizumab[14][15] and
infliximab.[16][17]
^Maska, L.; Anderson, J.; Michaud, K. (November 2011). "Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL)". Arthritis Care & Research. 63 (Supplement S11): S4–S13.
doi:
10.1002/acr.20620.
PMID22588760.
^Marra, Carlo A.; Woolcott, John C.; Kopec, Jacek A.; Shojania, Kamran; Offer, Robert; Brazier, John E.; Esdaile, John M.; Anis, Aslam H. (April 2005). "A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis". Social Science & Medicine. 60 (7): 1571–1582.
doi:
10.1016/j.socscimed.2004.08.034.
PMID15652688.
^Lillegraven, Siri; Kvien, Tore K. (October 2007). "Measuring disability and quality of life in established rheumatoid arthritis". Best Practice & Research Clinical Rheumatology. 21 (5): 827–840.
doi:
10.1016/j.berh.2007.05.004.
PMID17870030.
^"Measures Database". Galen-Research.com. Galen Research. Retrieved 2 October 2013.
^Eberhardt, Kerstin; Duckberg, Siv; Larsson, Britt-Marie; Johnson, Pia Malcus; Nived, Kerstin (July 2009). "Measuring health related quality of life in patients with rheumatoid arthritis – reliability, validity, and responsiveness of a Swedish version of RAQoL". Scandinavian Journal of Rheumatology. 31 (1): 6–12.
doi:
10.1080/030097402317255291.
PMID11922201.
S2CID42285569.
^Quinn, Mark A.; Conaghan, Philip G.; O'Connor, Philip J.; Karim, Zunaid; Greenstein, Adam; Brown, Andrew; Brown, Clare; Fraser, Alexander; Jarret, Stephen; Emery, Paul (January 2005). "Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial". Arthritis & Rheumatism. 52 (1): 27–35.
doi:
10.1002/art.20712.
PMID15641102.